TY - JOUR T1 - A cell phone data driven time use analysis of the COVID-19 epidemic JF - medRxiv DO - 10.1101/2020.04.20.20073098 SP - 2020.04.20.20073098 AU - Eli P. Fenichel AU - Kevin Berry AU - Jude Bayham AU - Gregg Gonsalves Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/23/2020.04.20.20073098.abstract N2 - Transmission of the SAR-COV-2 virus that causes COVID-19 is largely driven by human behavior and person-to-person contact. By staying home, people reduce the probability of contacting an infectious individual, becoming infected, and passing on the virus. One of the most promising sources of data on time use is smartphone location data. We develop a time use driven proportional mixing SEIR model that naturally incorporates time spent at home measured using smartphone location data and allows people of different health statuses to behave differently. We simulate epidemics in almost every county in the United States. The model suggests that Americans’ behavioral shifts have reduced cases in 55%-86% of counties and for 71%-91% of the population, depending on modeling assumptions. Resuming pre-epidemic behavior would lead to a rapid rise in cases in most counties. Spatial patterns of bending and flattening the curve are robust to modeling assumptions. Depending on epidemic history, county demographics, and behavior within a county, returning those with acquired immunity (assuming it exists) to regular schedules generally helps reduce cumulative COVID-19 cases. The model robustly identifies which counties would experience the greatest share of case reduction relative to continued distancing behavior. The model occasionally mischaracterizes epidemic patterns in counties tightly connected to larger counties that are experiencing large epidemics. Understanding these patterns is critical for prioritizing testing resources and back-to-work planning for the United States.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is either publicly or available for COVID-19 researchers from Safe Graph. Code will be made available following peer-reviewed publication (if not sooner). ER -